Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise

MT Newswires Live

2025/08/29

Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.

Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.

Analysts at Visible Alpha forecasted a loss of 1.01 yuan.

Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.

Analysts at Visible Alpha estimated 545.9 million yuan in revenue.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2563962970"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563962970\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563962970?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563962970","market":"sg","top_or_hot":-1,"title":"Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise","media":"MT Newswires Live","content":"<html><body><p> Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.</p><p>Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.</p><p>Analysts at Visible Alpha forecasted a loss of 1.01 yuan.</p><p>Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.</p><p>Analysts at Visible Alpha estimated 545.9 million yuan in revenue.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Everest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEverest Medicines' H1 Loss Narrows as Revenue Sees Sharp Rise\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-08-29 09:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.</p><p>Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.</p><p>Analysts at Visible Alpha forecasted a loss of 1.01 yuan.</p><p>Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.</p><p>Analysts at Visible Alpha estimated 545.9 million yuan in revenue.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"雲頂新耀","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2563962970","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563962970","pubTimestamp":1756431367,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Everest Medicines  reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.Analysts at Visible Alpha forecasted a loss of 1.01 yuan.Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.Analysts at Visible Alpha estimated 545.9 million yuan in revenue.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀","MDCO":"麦迪逊医药"},"translate_title":"Everest Medicines上半年亏损收窄，收入大幅增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":0.9,"MDCO":1},"content_text":"Everest Medicines (HKG:1952) reported 249.8 million yuan in attributable loss for the first half of 2025, narrowing from a loss of 632.4 million yuan a year earlier, according to a Hong Kong bourse filing Friday.Loss per share was 0.77 yuan, compared with 1.97 yuan in the prior year.Analysts at Visible Alpha forecasted a loss of 1.01 yuan.Revenue rose 48% year-on-year to 446.1 million yuan, figures showed. Sales rose primarily due to the continued commercialization of the company's Nefecon and Xerava therapies, the firm said.Analysts at Visible Alpha estimated 545.9 million yuan in revenue.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}